Skip to main content

Table 2 Summary of the percentage of WHO type I tumors and outcome on overall survival

From: The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase iii randomized trials

Study Trials included Patients with WHO type I tumors OR/HR/RR
   CCRT RT Total (%) 2 yrs 3 yrs 5 yrs
Huncharek et al [2] 2002* Al-Sarraf et al [1] 17/78 19/69 36/147 (24%) 0.16 0.16 0.16
Langendijk et al [3] 2004# Al-Sarraf et al [1] 17/78 19/69 48/781 (6%) NA NA 0.48
  Lin et al [8] 3/141 6/143     
  Chan et al [25] 2/174 1/176     
Baujat et al [5] 2006# Al-Sarraf et al [1] 17/78 19/69 41/716 (6%) NA NA 0.60
  Chan et al [11] 2/174 1/176     
  Kwong et al [10]
a). Concurrent
b). Conc. +AC
1/53
0/57
1/55
0/54
    
Our study 2010§ Kwong et al [10] 1/110 1/55 5/1608 (0.31%) 0.63 0.76 0.74
  Chan et al [11] 2/174 1/176     
  Wee et al [12] 0/111 0/110     
  Lee et al [13, 18] 0/172 0/176     
  Zhang et al [14] 0/59 0/56     
  Lee et al [15, 17] 0/51 0/42     
  Chen et al [16] 0/158 0/158     
  1. Abbreviations: OR = Odds Ratio, HR = Hazard Ratio, RR = Relative risk (*used OR, #used HR,§used RR in the analysis), NA = Not Available